Clinical trials: Clostridioides Difficile Infection, open to volunteers
Clostridioides Difficile Infection, Recurrent Infection
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year.
- Trial name
- LIVEDIFF (NCT06306014)
- Testing
- EXL01
- Where
- 10 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at…
- Trial name
- CEFTA (NCT03712722)
- Testing
- Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- University of Aarhus
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Clostridioides Difficile Infection
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin…
- Trial name
- FENDER (NCT05266807)
- Testing
- oral capsulized Fecal Microbiota Transplantation, Vancomycin or Fidaxomicin
- Where
- 8 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Benoit Guery
Clostridioides Difficile Infection
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling.
- Trial name
- NCT07613645
- Testing
- Health counseling sessions, Diet (control diet), Diet (experimental diet)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode.
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease
- Trial name
- SPORES-V (NCT06979609)
- Testing
- Oral Vancomycin Prophylaxis
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridioides Difficile Infection Recurrence
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C.
- Trial name
- NCT07250724
- Testing
- Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bactolife A/S
Ulcerative Colitis, Inflammatory Bowel Diseases
Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population
This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale…
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Clostridioides Difficile Infection
- Trial name
- FRONTIER-UC (NCT07401680)
- Testing
- Lyophilized Fecal Microbiota Transplantation (LFMT)
- Where
- 2 sites in Canada
- Volunteers
- 85 people
- Sponsor
- University of Alberta
Clostridioides Difficile Infection
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment
The goal of this observational study is to learn about the long-term effects of fecal microbiota transplantation (FMT) compared with antibiotic-only treatment in adults who were treated for Clostridioides difficile infection…
- Trial name
- LTO-CDI (NCT07569380)
- Where
- Sweden
- Volunteers
- 250 people
- Sponsor
- Umeå University
Clostridioides Difficile Infection
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C.
- Trial name
- PREVENT (NCT06884748)
- Testing
- Ursodiol 500 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Clostridioides Difficile Infection Recurrence, FMT
FMT Capsules for rCDI
Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
- Trial name
- FMT CAP CDI (NCT07458984)
- Testing
- Healthy donor stool
- Where
- Finland
- Volunteers
- 76 people
- Sponsor
- Helsinki University Central Hospital
Clostridioides Difficile Infection Recurrence
Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
Clostridioides difficile infection (CDI) is the most common cause of nosocomial diarrhea, and the most common health care-associated infectious disease in the United States, accounting for 15% of overall infections, nearly 30.000…
- Trial name
- NCT05739825
- Testing
- FMT from healthy donors
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients.
- Trial name
- NCT05852587
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Brigham and Women's Hospital
Clostridioides Difficile Infection
Clostridioides Difficile: Understanding Responses and Treatment Effects
The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery.
- Trial name
- CURE-CDI (NCT07374094)
- Testing
- Antibiotic treatment, Fecal microbiota transplantation (FMT)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Umeå University
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
- Trial name
- NCT06799039
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Brigham and Women's Hospital
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
This is a randomized, double-blind study to assess the safety and efficacy of fidaxomicin compared to vancomycin for decolonization of C. difficile in IBD patients.
- Trial name
- NCT06794944
- Testing
- Vancomycin (POC), Fidaxomicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care…
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT), Comparative Effectiveness of CDI Treatments
- Trial name
- STOP-CDI (NCT07120490)
- Testing
- FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment
- Volunteers
- 424 people
- Sponsor
- Medical University of Warsaw
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc